Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Linvolseltamab (anticorpo biespecífico anti-BCMA x anti-CD3) mais outros tratamentos de câncer para participantes com mieloma múltiplo recidivante/refratário (LINKER-MM2)

2 de novembro de 2026 atualizado por: Regeneron Pharmaceuticals

Estudo de fase 1b de REGN5458 (anticorpo biespecífico anti-BCMA x anti-CD3) mais outros tratamentos de câncer para pacientes com mieloma múltiplo recidivante/refratário

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.

In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies).

This study is the first time linvoseltamab will be combined with other cancer therapies.

The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination.

The study is looking at several other research questions, including:

  • How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma
  • What side effects may happen from taking linvoseltamab together with another cancer treatment
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

317

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Barcelona, Espanha, 08035
        • Recrutamento
        • Hospital Universitario Vall d'Hebron
      • Barcelona, Espanha, 08036
        • Recrutamento
        • Hospital Clinic de Barcelona
      • Barcelona, Espanha, 08908
        • Recrutamento
        • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
      • Madrid, Espanha, 28050
        • Recrutamento
        • Hospital Universitario HM Sanchinarro
      • Madrid, Espanha, 28027
        • Recrutamento
        • Clinica Universidad de Navarra - Madrid
      • Madrid, Espanha, 28006
        • Recrutamento
        • Universitaru Hospital La Princesa
      • Madrid, Espanha, 28041
        • Recrutamento
        • University Hospital and Research Institute
      • Madrid, Espanha, 28034
        • Recrutamento
        • Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
      • Salamanca, Espanha, 37007
        • Recrutamento
        • University Hospital of Salamanca
    • A Coruna
      • Santiago de Compostela, A Coruna, Espanha, 15706
        • Recrutamento
        • Hospital Clinico Universitario de Santiago
    • Barcelona
      • Badalona, Barcelona, Espanha, 08916
        • Recrutamento
        • Hospital Germans Trias i Pujol
    • Cantabria
      • Santander, Cantabria, Espanha, 39008
        • Recrutamento
        • Hospital Universitario Marques de Valdecilla
    • Madrid
      • Pozuelo de Alarcón, Madrid, Espanha, 28223
        • Recrutamento
        • Hospital Universitario Quiron Salud Madrid
    • Navarre
      • Pamplona, Navarre, Espanha, 31008
        • Recrutamento
        • Clinica Universidad de Navarra
    • California
      • La Jolla, California, Estados Unidos, 92037
        • Recrutamento
        • Scripps Clinic Torrey Pines
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30004
        • Recrutamento
        • Winship Cancer Institute of Emory University
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Recrutamento
        • Indiana University Health Simon Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Recrutamento
        • Dana Farber/Harvard Cancer Center
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48201
        • Recrutamento
        • Karmanos Cancer Institute
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic
    • New York
      • New York, New York, Estados Unidos, 10021
        • Recrutamento
        • Weill Cornell Medicine/New York Presbyterian Hospital
      • New York, New York, Estados Unidos, 10032
        • Recrutamento
        • New York Presbyterian Hospital Columbia University Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • Recrutamento
        • University of North Carolina at Chapel Hill
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Recrutamento
        • Wake Forest University Health Sciences
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • The Ohio State University James Cancer Hospital
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • Recrutamento
        • University of Texas Southwestern
    • Washington
      • Seattle, Washington, Estados Unidos, 98108
        • Recrutamento
        • VA Puget Sound Health Care System
      • Angers, França, 49933
        • Recrutamento
        • Centre Hospitalier Universitaire Angers
      • Montpellier, França, 34295
        • Recrutamento
        • CHU Montpellier - Departement D'Hematologie
      • Paris, França, 75571
        • Recrutamento
        • Saint Antoine Hospital
      • Villejuif, França, 94805
        • Recrutamento
        • Institut Gustave Roussy
    • New Aquitaine
      • Poitiers, New Aquitaine, França, 86021
        • Recrutamento
        • Centre Hospitalier Universitaire (CHU) de Poitiers
    • Nord
      • Lille, Nord, França, 59037
        • Recrutamento
        • CHU de Lille - Rue Michel Polonovski
    • Pays de la Loire Region
      • Nantes, Pays de la Loire Region, França, 44093
        • Recrutamento
        • Nantes University Hospital
    • Île-de-France Region
      • Créteil, Île-de-France Region, França, 94000
        • Recrutamento
        • Hospital Henri Mondor
      • Paris, Île-de-France Region, França, 75015
        • Recrutamento
        • Hopital Necker
      • Paris, Île-de-France Region, França, 75010
        • Recrutamento
        • Saint Louis Hospital
      • Athens, Grécia, 11528
        • Recrutamento
        • General Hospital of Athens Alexandra
    • Attica
      • Athens, Attica, Grécia, 10676
        • Recrutamento
        • Evangelismos General Hospital
      • Haifa, Israel, 3109601
        • Recrutamento
        • Rambam Health Care Campus
      • Jerusalem, Israel, 91120
        • Recrutamento
        • Hadassah Medical Center
    • Central District
      • Ramat Gan, Central District, Israel, 5265601
        • Recrutamento
        • Sheba Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

General Key Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  2. Participants must have measurable disease as defined in the protocol according to IMWG consensus criteria
  3. Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol
  4. Life expectancy of at least 6 months

Cohort Specific Inclusion Criteria:

For cohorts 1-6, each participant must have RRMM with progression following at least 3 lines of therapy, or at least 2 lines of therapy and either prior exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD) and 1 Proteasome Inhibitor (PI), or double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD Cohort 1: Prior treatment with daratumumab is allowed if previously tolerated, as described in the protocol Cohort 2: Prior treatment with carfilzomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 3: Prior treatment with lenalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 4: Prior treatment with bortezomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 5: Prior treatment with pomalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 6: Prior treatment with isatuximab is allowed if previously tolerated, as described in the protocol

Cohort 7 and 8:

  1. For participants without measurable disease by biochemical parameters [serum or urine M-protein, or serum involved Free Light Chain (FLC)], presence of at least 1 soft tissue plasmacytoma with a single diameter of ≥2 cm
  2. RRMM with progressive disease and received at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI or triple-class refractory disease (anti-CD38 antibody, IMiD, PI) Cohort 9: Progressive RRMM in participants with triple-class refractory disease (anti-CD38 antibody, IMiD, PI) after at least 3 lines of therapy Cohort 10: Progressive RRMM after at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI

General Key Exclusion Criteria:

  1. Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (excluding myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
  2. Participants with known MM brain lesions or meningeal involvement
  3. Treatment with any systemic anti-myeloma therapy within 5 half-lives or within 21 days prior to first administration of study drug regimen, whichever is shorter
  4. History of allogeneic and autologous stem cell transplantation, as described in the protocol
  5. Unless stated otherwise in a specific sub-protocol, prior treatment with a T cell-based immunotherapy directed against B-Cell Maturation Antigen (BCMA) bispecific antibodies and Bispecific T-cell Engagers (BiTEs), and BCMA Chimeric Antigen Receptor (CAR) T cells (Note: BCMA antibody-drug conjugates are not excluded)
  6. History of progressive multifocal leukoencephalopathy, neurodegenerative condition or Central Nervous System (CNS) movement disorder or participants with a history of seizure within 12 months prior to study enrollment are excluded
  7. Live or attenuated vaccination within 28 days prior to first study drug regimen administration with a vector that has replicative potential
  8. Cardiac ejection fraction <40% by Echocardiogram (Echo) or Multigated Acquisition (MUGA) scan

Cohort Specific Exclusion Criteria:

Cohort 2: Dose expansion: Prior treatment with a BCMA-directed CAR T-cell therapy will not be exclusionary if completed at least 12 weeks prior to first study treatment Cohort 3: Known malabsorption syndrome or pre-existing gastrointestinal (GI) condition that may impair absorption of lenalidomide; delivery of lenalidomide via nasogastric tube or gastrostomy tube is not allowed Cohort 4: Peripheral neuropathy grade ≥2 Cohort 5: Known malabsorption syndrome or pre-existing GI conditions that may impair absorption of pomalidomide; delivery of pomalidomide via nasogastric tube or gastrostomy tube is not allowed

Cohort 7:

  1. Prior treatment with anti-Lymphocyte Activation Gene 3 (LAG-3) agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Programmed cell Death Protein 1 (PD-1) antibodies is permitted, as described in the protocol
  2. Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol
  3. Prior solid organ transplant
  4. History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies

Cohort 8:

  1. Prior treatment with anti-PD-1 or anti-PD-L1 agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) antibodies is permitted, as described in the protocol
  2. Encephalitis or meningitis in the year prior to enrollment
  3. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment
  4. Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol.
  5. Prior solid organ transplant
  6. History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies

Cohort 9:

  1. Abnormal QT interval corrected by Fridericia's formula (QTcF), as described in the protocol
  2. Use of concomitant medications that are known to prolong the QT/QTcF interval including Class Ia and Class III antiarrhythmics at the time of informed consent
  3. Ongoing use or anticipated use of food or drugs that are known strong/moderate cytochrome P450 (CYP)3A4 inhibitors, or strong CYP3A inducers within 14 days prior to first dose of nirogacestat
  4. Known malabsorption syndrome or existing gastrointestinal GI condition that may impair absorption of nirogacestat; delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed

Cohort 10:

  1. Known or suspected active Epstein-Barr Virus (EBV) infection
  2. Known history of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
  3. Prior treatment with cevostamab or another agent with the same target [Fragment crystallizable Receptor-like 5 (FcRH5)]

Dose finding portion: Prior treatment with any BCMA-directed immunotherapy will not be exclusionary, as described in the protocol Dose expansion portion: Prior treatment with any T cell-engaging bispecific antibody directed against BCMA will be exclusionary, as described in the protocol

NOTE: Other protocol defined inclusion/exclusion criteria apply

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Cohort 1: Linvoseltamab + Daratumumab

Linvoseltamab + Daratumumab

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • Darzalex®; Darzalex Faspro™
Experimental: Cohort 2: Linvoseltamab + Carfilzomib

Linvoseltamab + Carfilzomib

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • Kyprolis®
Experimental: Cohort 3: Linvoseltamab + Lenalidomide

Linvoseltamab + Lenalidomide

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • Revlimid®
Experimental: Cohort 4: Linvoseltamab + Bortezomib

Linvoseltamab + Bortezomib

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • Velcade®
Experimental: Cohort 5: Linvoseltamab + Pomalidomide

Linvoseltamab + Pomalidomide

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • Imnovid, Pomalyst®
Experimental: Cohort 6: Linvoseltamab + Isatuximab

Linvoseltamab + Isatuximab

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • Sarclisa®
Experimental: Cohort 7: Linvoseltamab + Fianlimab

Linvoseltamab + Fianlimab

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • REGN3767
Experimental: Cohort 8: Linvoseltamab + Cemiplimab

Linvoseltamab + Cemiplimab

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • REGN2810
  • LIBTAYO
Experimental: Cohort 9: Linvoseltamab + Nirogacestat

Linvoseltamab + Nirogacestat

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • PF-03084014
Experimental: Cohort 10: Linvoseltamab + Cevostamab

Linvoseltamab + Cevostamab

Administered per the protocol

Outros nomes:
  • REGN5458
  • Lynozyfic ™

Administered per the protocol

Outros nomes:
  • RO7187797
  • BFCR4350A

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidência de Eventos Adversos Graves (SAEs)
Prazo: Até 5 anos
Até 5 anos
Gravidade dos TEAEs
Prazo: Até 5 anos
Até 5 anos
Gravidade dos SAEs
Prazo: Até 5 anos
Até 5 anos
Gravidade de AESIs
Prazo: Até 5 anos
Até 5 anos
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Prazo: Up to 5 Years
Up to 5 Years
Incidence of Adverse Events of Special Interest (AESIs)
Prazo: Up to 5 Years
Up to 5 Years
Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period
Prazo: Up to 28 Days

Dose finding portion only

Up to 28 Days
Incidence of laboratory abnormalities
Prazo: Up to 5 Years

≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v5.0]

Up to 5 Years

Medidas de resultados secundários

Medida de resultado
Prazo
Sobrevivência geral (OS)
Prazo: Até 5 anos
Até 5 anos
Concentrações de linvoseltamab total no soro ao longo do tempo
Prazo: Até 5 anos
Até 5 anos
Overall Response Rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria
Prazo: Up to 5 Years
Up to 5 Years
Duration of Response (DOR) by IMWG criteria
Prazo: Up to 5 Years
Up to 5 Years
Progression-Free Survival (PFS) as measured by IMWG criteria
Prazo: Up to 5 Years
Up to 5 Years
Rate of Minimal Residual Disease (MRD) negative status by IMWG criteria
Prazo: Up to 5 Years
Up to 5 Years
Incidence over time of Anti-Drug Antibodies (ADAs) to linvoseltamab
Prazo: Up to 5 Years
Up to 5 Years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Clinical Trial Management, Regeneron Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de agosto de 2022

Conclusão Primária (Estimado)

25 de março de 2028

Conclusão do estudo (Estimado)

24 de março de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

18 de novembro de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de novembro de 2021

Primeira postagem (Real)

30 de novembro de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Prazo de Compartilhamento de IPD

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Critérios de acesso de compartilhamento IPD

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever